Jung Hoon Kim MD, Presenter: Nothing to Disclose

Jeehyun Kim, Abstract Co-Author: Nothing to Disclose

Hyo Won Eun MD, PhD, Abstract Co-Author: Nothing to Disclose

Joon Koo Han MD, Abstract Co-Author: Nothing to Disclose

Byung Ihn Choi MD, PhD, Abstract Co-Author: Research Consultant, Samsung Electronics Co Ltd

Tumor size and vascularity are most important parameters for therapeutic response evaluation. This study is to assess the feasibility of tumor volume measurement and volumetric contrast-enhanced US using 3D transducer in therapeutic response evaluation after treatment in VX2 rabbit hepatic tumor comparison with 2D-CEUS.

Rabbit hepatic VX2 carcinoma with targeted therapy(n=22, 30mg/kg/day of Sorafenib for 7-day) and control group(n=13) were performed CEUS using 2D(12MHz, PLT-1204MV) and 3D transducer(12MHz, PLT-1204BT) baseline and one day after first treatment. Three different tumor volumes(calculated volume from 2D US; 2D-Vol, 3D volume identified on non-contrast US; 3D-Vol, 3D volume identified on CEUS; e3D-Vol) and seven US perfusion parameters were obtained. Tumor volume using MDCT as a reference standard, we compared the change of each different tumor volumes. Therapeutic efficacy was estimated using necrotic fraction, MVD, and apoptosis of tumor after treatment. Correlation between tumor volume and US perfusion parameters was analyzed. 

According to pathology, there were significant different between baseline and after treatment. Tumor volume showed no statistical difference between baseline and one day after first treatment(299.9 ±140.6 vs 283.7 ±118.1, mm3, p=.108), however, in treatment group, both 3D and 2D US perfusion parameters, including peak intensity(33.2±19.9 vs 16.6±10.7, 63.7±20.0 vs 30.1±19.8), slope(15.3±12.4 vs 5.7±4.5, 37.3±20.4 vs 15.7±13.0), AUC(1004.1±560.3 vs 611.4±421.1, 1332.2±708.3 vs 670.4±388.3), had significantly decreased one day following first treatment(p=.00). e3D-Vol showed no statistical difference comparison with tumor volume using MDCT(299.9± 140.6mm3 vs 283.7±118.1, p= .108), however 2D-Vol(1933.7±1250.4, p= .00) and 3D-Vol(236.8±118.0, p=.00) had significant difference comparison with tumor volume using MDCT.

CEUS using 3D transducer was useful for predicting early therapeutic response one day after targeted therapy using US perfusion parameters. In addition to, CEUS using 3D transducer is accurately measure the tumor volume.

CEUS using 3D transducer is feasible to predict therapeutic response evaluation after targeted therapy because it is not only useful for perfusion evaluation but also accurate tumor volume measurement.

Kim, J, Kim, J, Eun, H, Han, J, Choi, B, Feasibility of Volumetric Contrast-Enhanced US and Tumor Volume Measurement Using 3D Transducer in Therapeutic Response Evaluation after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma Comparison with 2D-CEUS.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14010411.html